[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"thoracic-tumor\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:thoracic-tumor":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,55,82],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":35,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":54},"100443348","a-study-evaluating-the-integrative-medicine-at-home-imhome-program-in-people-with-cancer-100443348",false,"NCT05053230","A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer","Integrative Medicine for Patient-reported Outcomes, Values, and Experience (IMPROVE)","IMPROVE","Inclusion Criteria:\n\n* Age ≥ 18 years or older\n* Karnofsky score 60 or greater\n* Life expectancy greater than six months\n* English speaking\n\nAdditional Inclusion Criteria for Head and Neck, Thoracic, Gynecologic, Melanoma and Breast Baskets\n\n* Patients with a diagnosis of head and neck tumors, thoracic tumors, gynecological tumors, melanoma, breast cancer, or gynecologic cancer\n* Actively receiving systemic oncological treatment or radiotherapy, or within 4 weeks of radiotherapy completion or primary cytoreductive surgery\n* Worst fatigue over the last 7 days rated 4 or greater on (0-10 scale)\n\nAdditional Inclusion Criteria for First Remission Gynecologic Cancer Basket\n\n* Patients with a diagnosis or clinical suspicion of gynecologic malignancy who have completed definitive first line treatment (maintenance hormonal or targeted therapies are allowed)\n\nAdditional Inclusion Criteria for the Advanced Cancer Basket:\n\n* Patients with a diagnosis of Stage III or IV lung cancer; any stage pancreatic cancer, unresectable cholangiocarcinoma, unresectable liver cancer, unresectable ampullary or peri-ampullary cancer, or other stage IV gastrointestinal cancer; stage III or IV ovarian or fallopian tube cancers or other stage IV gynecologic cancer; stage IV breast cancer; stage III testicular cancer or any stage IV genitourinary cancer; stage IV sarcoma; stage IV melanoma; stage IV endocrine cancer; lymphoma, myeloma, or Leukemia\n* Actively receiving oncological treatment, radiotherapy or active surveillance\n\nAdditional Inclusion Criteria for the Cancer Survivor Basket:\n\n* Completed active cancer treatment (e.g., surgery, radiation, chemotherapy) (maintenance hormonal or targeted therapies are allowed).\n* Worst fatigue over the last 7 days rated 4 or greater on (0-10 scale)\n\nExclusion Criteria:\n\n* Cognitive impairment that would preclude response to study assessments or require the use of Legally Authorized Representatives\n* Unwilling to accept random assignment\n* Concurrently enroll onto ongoing competing trials of integrative medicine interventions with symptom\u002Ftoxicity as primary outcome. Note, however, patient will be allowed to enroll on other therapeutic protocols","ALL","18 Years",{"count":20,"type":21},480,"ESTIMATED","INTERVENTIONAL",[24],"NA","The overarching long-term goal of the Integrative Medicine for Patient-reported Outcomes Values and Experience (IMPROVE) research program is to evaluate whether integrating a virtual mind-body programming, Integrative Medicine at Home (IM@Home), will improve patient perceived values, outcomes, and experiences as they undergo systemic cancer treatment such as chemotherapy, immunotherapy, radiotherapy, targeted agents, cytoreductive surgery.",[27,28,29,30,31,32,33,34],"Head and Neck Cancer","Head and Neck Tumor","Thoracic Tumor","Thoracic Cancer","Gynecologic Cancer","Gynecologic Tumor","Melanoma","Ovarian Cancer",[27,36,37,38,39,40,41,42],"head and neck tumor","thoracic tumors","gynecological tumors","melanoma","21-369","Memorial Sloan Kettering Cancer Center","ovarian cancer","RECRUITING","2025-10-08",{"date":46,"type":47},"2025-10-09","ACTUAL",{"date":49,"type":47},"2021-09-20",{"date":51,"type":21},"2026-09-20",{"name":41,"class":53},"OTHER",7,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":63,"targetDuration":65,"studyType":66,"phases":4,"briefSummary":67,"conditions":68,"keywords":70,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":81},"100530306","pelvic-cancer-registry-for-online-adapted-radiotherapy-100530306","NCT06185062","Pelvic Cancer Registry for Online Adapted Radiotherapy","Pelvic and Thoracic Cancer Treated With Online Adapted Radiotherapy: A Prospective Registry-based Phase-II Trial","PRoART","INCLUSION CRITERIA\n\n* Patients with pelvic or thoracic tumors with an indication for radiotherapy\n* Patient information and declaration of consent\n* Patients age ≥ 18 years\n\nEXCLUSION CRITERIA\n\n* Prior radiotherapy in affected site",{"count":64,"type":21},846,"5 Years","OBSERVATIONAL","This prospective registry-based trial will include patients with pelvic or thoracic tumors with an indication for radiotherapy treated with oART or IGRT. For the primary endpoint and the secondary clinical endpoints, the trial will compare oART versus IGRT, for technical endpoints the trial will compare the real oART scenario with two virtual (hypothetical) control scenarios.\n\nPrimary endpoint:\n\n* 10% reduction in the rate of acute radiotherapy related toxicity (≥ CTCAE II°, v5.0) using oART\n\nSecondary endpoints:\n\n* Clinical endpoints: Tumor control, late toxicities compared to conventional irradiated patients, quality of life and patient-reported outcomes\n* Technical endpoints: Target volume, target coverage, dose to organs at risk, anatomical variability score",[69,29],"Pelvic Tumor",[71],"online Adaptive Radiotherapy","2024-02-06",{"date":74,"type":47},"2024-02-08",{"date":76,"type":47},"2024-01-01",{"date":78,"type":21},"2030-04",{"name":80,"class":53},"University Medical Center Goettingen",1,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":66,"phases":4,"briefSummary":91,"conditions":92,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":81},"100453785","safety-and-efficacy-of-sbrt-in-the-reirradiation-for-ultra-central-thoracic-malignant-tumors-100453785","NCT05189054","Safety and Efficacy of SBRT in the Reirradiation for Ultra-central Thoracic Malignant Tumors","Inclusion Criteria:\n\n* Pathological diagnosis is malignant tumor.\n* The location of the target lesion belongs to the ultra-central type of chest.\n* The target lesion had a history of radiotherapy, and the lesion diameter is ≤ 5cm.\n* There is no extensive systemic metastasis or although there is metastasis, the metastasis have been controlled by previous treatment.\n* KPS\\>70, no serious or uncontrolled underlying diseases, such as severe or uncontrolled hypertension, diabetes, cardiovascular and cerebrovascular diseases and organ dysfunction, and patients are expected to be tolerated by radiotherapy.\n\nExclusion Criteria:\n\n* Poor basic pulmonary function or symptom correlation caused by various reasons, unable to lie flat or cooperate with treatment.\n* The general condition is poor, and the expected survival time is less than 3 months.\n* Psychiatric patients or poor compliance, unable to cooperate to complete treatment.\n* For other reasons, the researcher believes that it is not suitable to participate in this trial.","80 Years",{"count":90,"type":21},40,"The reirradiation of thoracic tumor is difficult. The possibility of surgery or re course radiotherapy is very small. In the NCCN guideline, only systemic treatment is recommended. However, the effective rate of systemic treatment is low. SBRT has the characteristics of high dose in tumor target area and low dose in surrounding normal tissues. In theory, SBRT is more conducive to the protection of normal tissues and can potentially be used in the salvage treatment of recurrent lesions after radiotherapy. Even so, SBRT is still controversial in the rescue treatment of recurrent lung cancer after radiotherapy, especially for \"ultral-central\" lesions close to mediastinal structures (such as bronchus, esophagus and large blood vessels), which have a high probability of fatal side effects. However, a few studies on the application of SBRT in the reirradiation for ultral-central lung cancer have shown acceptable safety and efficacy. Generally speaking, there are few studies on SBRT in the treatment of recurrent ultral-central tumor with limited data. The purpose of this study is to further evaluate the efficacy and toxicities of SBRT in the treatment of recurrent ultral-central tumors after radiotherapy.",[93,94,29,95],"Stereotactic Body Radiation Therapy","Irradiation; Reaction","Recurrent Cancer","2023-12-22",{"date":98,"type":47},"2023-12-27",{"date":100,"type":47},"2022-05-01",{"date":102,"type":21},"2027-04-30",{"name":104,"class":53},"Peking University Third Hospital"]